Trial Profile

A Phase II trial of ZLX-1 for treating stress-related insomnia.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Aug 2017 According to a Blake Insomnia Therapeutics media release, the company has submitted its clinical trial application (CTA) for Phase II clinical testing to Health Canada.
25 Feb 2017 According to a Blake Insomnia Therapeutics media release, company is planning to submit a New Drug Application in Canada with US in Q2 2017 and International submissions to follow later.
08 Feb 2017 According to Blake Insomnia Therapeutics media release, this trial is planned for Q2 2017, with successful filing and approval, the product is expected to be launched in the US in 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com